These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24166760)

  • 1. Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese subjects.
    Royalty JE; Konradsen G; Eskerod O; Wulff BS; Hansen BS
    J Clin Pharmacol; 2014 Apr; 54(4):394-404. PubMed ID: 24166760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single and multiple dose evaluation of a novel MetAP2 inhibitor: Results of a randomized, double-blind, placebo-controlled clinical trial.
    Malloy J; Zhuang D; Kim T; Inskeep P; Kim D; Taylor K
    Diabetes Obes Metab; 2018 Aug; 20(8):1878-1884. PubMed ID: 29577550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
    Enebo LB; Berthelsen KK; Kankam M; Lund MT; Rubino DM; Satylganova A; Lau DCW
    Lancet; 2021 May; 397(10286):1736-1748. PubMed ID: 33894838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study.
    Lin D; Xiao H; Yang K; Li J; Ye S; Liu Y; Jing S; Lin Y; Yang Y; Huang L; Yuan J; Li Z; Yang J; Gao H; Xie Y; Xu M; Yan L
    BMC Med; 2024 May; 22(1):209. PubMed ID: 38807146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
    Derks M; Anzures-Cabrera J; Turnbull L; Phelan M
    Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Setmelanotide (Imcivree) for rare genetic forms of obesity.
    Med Lett Drugs Ther; 2021 Jul; 63(1629):e3-e4. PubMed ID: 34544109
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes.
    Allas S; Delale T; Ngo N; Julien M; Sahakian P; Ritter J; Abribat T; van der Lely AJ
    Diabetes Obes Metab; 2016 Sep; 18(9):868-74. PubMed ID: 27063928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long-acting glucagon analogue HM15136 in overweight and obese patients with co-morbidities.
    Shin W; Hompesch M; Byeon J; Kang S; Choi J; Baek S
    Diabetes Obes Metab; 2023 Sep; 25(9):2723-2733. PubMed ID: 37311732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals.
    Chen KY; Muniyappa R; Abel BS; Mullins KP; Staker P; Brychta RJ; Zhao X; Ring M; Psota TL; Cone RD; Panaro BL; Gottesdiener KM; Van der Ploeg LH; Reitman ML; Skarulis MC
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1639-45. PubMed ID: 25675384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects.
    Önnestam K; Nilsson B; Rother M; Rein-Hedin E; Bylund J; Anderer P; Kemethofer M; Halldin MM; Sandin J; Segerdahl M
    J Prev Alzheimers Dis; 2023; 10(4):778-789. PubMed ID: 37874100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies.
    Bianzano S; Henrich A; Herich L; Kalsch B; Sarubbi D; Seitz F; Forst T
    Metabolism; 2023 Jun; 143():155550. PubMed ID: 36958671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteers.
    Haass-Koffler CL; Goodyear K; Long VM; Tran HH; Loche A; Cacciaglia R; Swift RM; Leggio L
    Eur J Pharm Sci; 2017 Nov; 109():78-85. PubMed ID: 28778464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
    Clément K; van den Akker E; Argente J; Bahm A; Chung WK; Connors H; De Waele K; Farooqi IS; Gonneau-Lejeune J; Gordon G; Kohlsdorf K; Poitou C; Puder L; Swain J; Stewart M; Yuan G; Wabitsch M; Kühnen P;
    Lancet Diabetes Endocrinol; 2020 Dec; 8(12):960-970. PubMed ID: 33137293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.
    Richard M; Kaufmann P; Ort M; Kornberger R; Dingemanse J
    CNS Drugs; 2020 Mar; 34(3):311-323. PubMed ID: 31994022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, pharmacodynamics, safety, and tolerability of pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor in overweight or obese, but otherwise healthy human subjects.
    Meyers CD; Amer A; Majumdar T; Chen J
    J Clin Pharmacol; 2015 Sep; 55(9):1031-41. PubMed ID: 25854859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma.
    Fowler A; Koenen R; Hilbert J; Blatchford J; Kappeler D; Benediktus E; Wood C; Gupta A
    J Clin Pharmacol; 2017 Nov; 57(11):1444-1453. PubMed ID: 28609567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants.
    Clayton AH; Lucas J; DeRogatis LR; Jordan R
    Clin Ther; 2017 Mar; 39(3):514-526.e14. PubMed ID: 28189361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial.
    Eliasson B; Gudbjörnsdottir S; Cederholm J; Liang Y; Vercruysse F; Smith U
    Int J Obes (Lond); 2007 Jul; 31(7):1140-7. PubMed ID: 17264849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus.
    Jain M; Carlson G; Cook W; Morrow L; Petrone M; White NE; Wang T; Naylor J; Ambery P; Lee C; Hirshberg B
    Diabetologia; 2019 Mar; 62(3):373-386. PubMed ID: 30593607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance.
    Aronne LJ; Finer N; Hollander PA; England RD; Klioze SS; Chew RD; Fountaine RJ; Powell CM; Obourn JD
    Obesity (Silver Spring); 2011 Jul; 19(7):1404-14. PubMed ID: 21293451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.